Phase Ib dose-escalation study of the selective, noncovalent, reversible Bruton’s tyrosine kinase inhibitor vecabrutinib in B-cell malignancies

Detalles Bibliográficos
Autores principales: Allan, John N., Pinilla-Ibarz, Javier, Gladstone, Douglas E., Patel, Krish, Sharman, Jeff P., Wierda, William G., Choi, Michael Y., O’Brien, Susan M., Shadman, Mazyar, Davids, Matthew S., Pagel, John M., Yimer, Habte A., Ward, Renee, Acton, Gary, Taverna, Pietro, Combs, Daniel L., Fox, Judith A., Furman, Richard R., Brown, Jennifer R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Fondazione Ferrata Storti 2021
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968902/
https://www.ncbi.nlm.nih.gov/pubmed/34937320
http://dx.doi.org/10.3324/haematol.2021.280061

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8968902/
https://www.ncbi.nlm.nih.gov/pubmed/34937320
http://dx.doi.org/10.3324/haematol.2021.280061

Ejemplares similares